The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt thereof, that inhibit phosphoinositide 3-kinase;
methods of treating diseases or conditions, such as cancer, using the compounds; and pharmaceutical compositions containing the compounds.
[EN] FUSED BICYCLIC COMPOUNDS AS INHIBITORS FOR PI3 KINASE<br/>[FR] COMPOSÉS BICYCLIQUES FUSIONNÉS UTILISÉS COMME INHIBITEURS DE LA PI3 KINASE
申请人:MERCK SERONO SA
公开号:WO2010100144A1
公开(公告)日:2010-09-10
The invention relates to compounds of formula (I) for the regulation of phosphoinositides 3-kinases activity and related diseases.
该发明涉及用于调节磷脂酰肌醇3-激酶活性及相关疾病的化合物(I)的公式。
US7820665B2
申请人:——
公开号:US7820665B2
公开(公告)日:2010-10-26
[EN] INHIBITORS OF PI3 KINASE<br/>[FR] INHIBITEURS DE LA PI3 KINASE
申请人:AMGEN INC
公开号:WO2009085230A1
公开(公告)日:2009-07-09
The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt thereof, that inhibit phosphoinositide 3-kinase; Formula (I) methods of treating diseases or conditions, such as cancer, using the compounds; and pharmaceutical compositions containing the compounds.
[EN] INDAZOLES AS HEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) INHIBITORS AND METHODS FOR USING SAME<br/>[FR] INDAZOLES UTILISÉS EN TANT QU'INHIBITEURS DE KINASE PROGÉNITRICE HÉMATOPOÏÉTIQUE 1 (HPK1) ET LEURS PROCÉDÉS D'UTILISATION
申请人:[en]1ST BIOTHERAPEUTICS, INC.
公开号:WO2023180976A1
公开(公告)日:2023-09-28
The present disclosure provides a compound of Formula (I) or pharmaceutically acceptable salts thereof, a composition comprising the compound, methods of using the compound for the treatment of various disorders associated with HPK1, and methods of preparing these compounds.